Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy + Gefitinib vs Gefitinib in EGFR+ Lung Adenocarcinoma
NCT02951637Phase 2Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Dec 2016
- Primary completion
- Apr 2018
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, randomised, open-label trial of pemetrexed and carboplatin in lung adenocarcinoma (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Progression-Free Survival at 16 months. Status: unknown.
02
Drugs
pemetrexedcarboplatin
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02951637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02951637.